L-17 compound of the group of substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines was used to treat experimental pancreatonecrosis in rats. Aim. The aim of the study was to assess the possibility of correction of systemic inflammatory response in severe acute pancreatitis by the compound L-17 from the group of substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines. Materials and methods. The trial was carried out on 30 outbred female rats with the average body weight 180-240g. each. For getting statistically reliable results, the groups of 15 animals were formed. The formation of pancreatic necrosis in rats was produced according to the author’s model (PCT Patent RF № 2400820 of 01.09.2008). After the formation of experimental pancreatic necrosis the animals were treated intraperitoneally with the compound L-17 at a dose of 40 mg/kg. The control group included 15 animals with an average weight of 220 grams, with experimental pancreatonecrosis. Results. The development of systemic inflammation in a group of animals with experimental acute pancreatitis was confirmed by the appearance of significant signs of systemic inflammation, low levels of monocytes, high levels of IL-1, IL-6, IL-10 and TNF. The use of compound L-17 in the treatment of experimental pancreatonecrosis reduces mortality from complications of 2, being the effective method of correcting of the systemic inflammation. Conclusion. The mechanism of the influence of compound L-17 on the emergence and the development of systemic inflammation may lie in the fact that it reduces the severity of exudative-destructive (purulent) inflammation and stimulates the development of productive (cell proliferative) inflammation.